{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:20:31Z","timestamp":1790774431267,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001459","name":"Ministry of Education - Singapore","doi-asserted-by":"publisher","award":["MOE-T2EP30220-0013"],"award-info":[{"award-number":["MOE-T2EP30220-0013"]}],"id":[{"id":"10.13039\/501100001459","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1038\/s41375-024-02509-y","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T11:37:16Z","timestamp":1736249836000},"page":"650-662","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["EZH2 modulates mRNA splicing and exerts part of its oncogenic function through repression of splicing factors in CML"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7545-2819","authenticated-orcid":false,"given":"Reinhard","family":"Brunmeir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junli","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan Ting","family":"Hee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baohong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvinder","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao Zheng","family":"Leong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3647-0253","authenticated-orcid":false,"given":"Wei Wen","family":"Teo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2239-6420","authenticated-orcid":false,"given":"Gerald","family":"Choong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9339-3362","authenticated-orcid":false,"given":"Wei-Ying","family":"Jen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang Piu","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lip Kun","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7392-0655","authenticated-orcid":false,"given":"Melissa","family":"Ooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1155-8216","authenticated-orcid":false,"given":"Henry","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2578-8335","authenticated-orcid":false,"given":"Wee Joo","family":"Chng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,7]]},"reference":[{"key":"2509_CR1","doi-asserted-by":"crossref","first-page":"R90","DOI":"10.1093\/hmg\/dds353","volume":"21","author":"SJ Brown","year":"2012","unstructured":"Brown SJ, Stoilov P, Xing Y. Chromatin and epigenetic regulation of pre-mRNA processing. Hum Mol Genet. 2012;21:R90\u201396.","journal-title":"Hum Mol Genet"},{"key":"2509_CR2","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1126\/science.1184208","volume":"327","author":"RF Luco","year":"2010","unstructured":"Luco RF, Pan Q, Tominaga K, Blencowe BJ, Pereira-Smith OM, Misteli T. Regulation of alternative splicing by histone modifications. Science. 2010;327:996\u20131000.","journal-title":"Science"},{"key":"2509_CR3","doi-asserted-by":"crossref","DOI":"10.1002\/wrna.1593","volume":"11","author":"M Tellier","year":"2020","unstructured":"Tellier M, Maudlin I, Murphy S. Transcription and splicing: a two-way street. Wiley Interdiscip Rev RNA. 2020;11:e1593.","journal-title":"Wiley Interdiscip Rev RNA"},{"key":"2509_CR4","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41568-022-00541-7","volume":"23","author":"RK Bradley","year":"2023","unstructured":"Bradley RK, Anczukow O. RNA splicing dysregulation and the hallmarks of cancer. Nat Rev Cancer. 2023;23:135\u201355.","journal-title":"Nat Rev Cancer"},{"key":"2509_CR5","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1101\/gad.338962.120","volume":"34","author":"S Cherry","year":"2020","unstructured":"Cherry S, Lynch KW. Alternative splicing and cancer: insights, opportunities, and challenges from an expanding view of the transcriptome. Genes Dev. 2020;34:1005\u201316.","journal-title":"Genes Dev"},{"key":"2509_CR6","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ccell.2018.07.001","volume":"34","author":"A Kahles","year":"2018","unstructured":"Kahles A, Lehmann KV, Toussaint NC, Huser M, Stark SG, Sachsenberg T, et al. Comprehensive analysis of alternative splicing across tumors from 8,705 patients. Cancer Cell. 2018;34:211\u201324.e216.","journal-title":"Cancer Cell"},{"key":"2509_CR7","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1038\/onc.2015.318","volume":"35","author":"A Sveen","year":"2016","unstructured":"Sveen A, Kilpinen S, Ruusulehto A, Lothe RA, Skotheim RI. Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes. Oncogene. 2016;35:2413\u201327.","journal-title":"Oncogene"},{"key":"2509_CR8","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1158\/0008-5472.CAN-20-2147","volume":"80","author":"ML Eich","year":"2020","unstructured":"Eich ML, Athar M, Ferguson JE 3rd, Varambally S. EZH2-targeted therapies in cancer: hype or a reality. Cancer Res. 2020;80:5449\u201358.","journal-title":"Cancer Res"},{"key":"2509_CR9","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm.4036","volume":"22","author":"KH Kim","year":"2016","unstructured":"Kim KH, Roberts CW. Targeting EZH2 in cancer. Nat Med. 2016;22:128\u201334.","journal-title":"Nat Med"},{"key":"2509_CR10","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/2159-8290.CD-16-0263","volume":"6","author":"MT Scott","year":"2016","unstructured":"Scott MT, Korfi K, Saffrey P, Hopcroft LE, Kinstrie R, Pellicano F, et al. Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine kinase inhibition. Cancer Discov. 2016;6:1248\u201357.","journal-title":"Cancer Discov"},{"key":"2509_CR11","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1158\/2159-8290.CD-15-1439","volume":"6","author":"H Xie","year":"2016","unstructured":"Xie H, Peng C, Huang J, Li BE, Kim W, Smith EC, et al. Chronic myelogenous leukemia- initiating cells require polycomb group protein EZH2. Cancer Discov. 2016;6:1237\u201347.","journal-title":"Cancer Discov"},{"key":"2509_CR12","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s11899-022-00679-z","volume":"17","author":"JJ Ng","year":"2022","unstructured":"Ng JJ, Ong ST. Therapy resistance and disease progression in CML: mechanistic links and therapeutic strategies. Curr Hematol Malig Rep. 2022;17:181\u201397.","journal-title":"Curr Hematol Malig Rep."},{"key":"2509_CR13","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1172\/JCI85239","volume":"126","author":"Y Jin","year":"2016","unstructured":"Jin Y, Zhou J, Xu F, Jin B, Cui L, Wang Y, et al. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia. J Clin Invest. 2016;126:3961\u201380.","journal-title":"J Clin Invest"},{"key":"2509_CR14","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.3390\/cancers14194695","volume":"14","author":"B Lebecque","year":"2022","unstructured":"Lebecque B, Bourgne C, Munje C, Berger J, Tassin T, Cony-Makhoul P, et al. The spliceosome: a new therapeutic target in chronic myeloid leukaemia. Cancers (Basel). 2022;14:4695.","journal-title":"Cancers (Basel)"},{"key":"2509_CR15","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1038\/s41375-020-0732-1","volume":"34","author":"JR Sinnakannu","year":"2020","unstructured":"Sinnakannu JR, Lee KL, Cheng S, Li J, Yu M, Tan SP, et al. SRSF1 mediates cytokine-induced impaired imatinib sensitivity in chronic myeloid leukemia. Leukemia. 2020;34:1787\u201398.","journal-title":"Leukemia"},{"key":"2509_CR16","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.3390\/ijms21113828","volume":"21","author":"O An","year":"2020","unstructured":"An O, Tan KT, Li Y, Li J, Wu CS, Zhang B, et al. CSI NGS portal: an online platform for automated NGS data analysis and sharing. Int J Mol Sci. 2020;21:3828.","journal-title":"Int J Mol Sci"},{"key":"2509_CR17","doi-asserted-by":"crossref","first-page":"W216","DOI":"10.1093\/nar\/gkac194","volume":"50","author":"BT Sherman","year":"2022","unstructured":"Sherman BT, Hao M, Qiu J, Jiao X, Baseler MW, Lane HC, et al. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 2022;50:W216\u2013W221.","journal-title":"Nucleic Acids Res"},{"key":"2509_CR18","volume":"6","author":"V Madan","year":"2015","unstructured":"Madan V, Kanojia D, Li J, Okamoto R, Sato-Otsubo A, Kohlmann A, et al. Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome. Nat Commun. 2015;6:6042.","journal-title":"Nat Commun"},{"key":"2509_CR19","first-page":"E5593","volume":"111","author":"S Shen","year":"2014","unstructured":"Shen S, Park JW, Lu ZX, Lin L, Henry MD, Wu YN, et al. rMATS: robust and flexible detection of differential alternative splicing from replicate RNA-Seq data. Proc Natl Acad Sci USA. 2014;111:E5593\u20135601.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2509_CR20","doi-asserted-by":"crossref","first-page":"W333","DOI":"10.1093\/nar\/gkw410","volume":"44","author":"JW Park","year":"2016","unstructured":"Park JW, Jung S, Rouchka EC, Tseng YT, Xing Y. rMAPS: RNA map analysis and plotting server for alternative exon regulation. Nucleic Acids Res. 2016;44:W333\u2013338.","journal-title":"Nucleic Acids Res"},{"key":"2509_CR21","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1093\/bib\/bbz126","volume":"21","author":"A Mehmood","year":"2020","unstructured":"Mehmood A, Laiho A, Venalainen MS, McGlinchey AJ, Wang N, Elo LL. Systematic evaluation of differential splicing tools for RNA-seq studies. Brief Bioinform. 2020;21:2052\u201365.","journal-title":"Brief Bioinform"},{"key":"2509_CR22","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1128\/MCB.21.4.1285-1296.2001","volume":"21","author":"AN Ladd","year":"2001","unstructured":"Ladd AN, Charlet N, Cooper TA. The CELF family of RNA binding proteins is implicated in cell-specific and developmentally regulated alternative splicing. Mol Cell Biol. 2001;21:1285\u201396.","journal-title":"Mol Cell Biol"},{"key":"2509_CR23","doi-asserted-by":"crossref","first-page":"E2139","DOI":"10.1073\/pnas.1423695112","volume":"112","author":"MJ Mallory","year":"2015","unstructured":"Mallory MJ, Allon SJ, Qiu J, Gazzara MR, Tapescu I, Martinez NM, et al. Induced transcription and stability of CELF2 mRNA drives widespread alternative splicing during T-cell signaling. Proc Natl Acad Sci USA. 2015;112:E2139\u20132148.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2509_CR24","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1016\/j.celrep.2019.08.022","volume":"28","author":"R Chatrikhi","year":"2019","unstructured":"Chatrikhi R, Mallory MJ, Gazzara MR, Agosto LM, Zhu WS, Litterman AJ, et al. RNA binding protein CELF2 regulates signal-induced alternative polyadenylation by competing with enhancers of the polyadenylation machinery. Cell Rep. 2019;28:2795\u2013806.e2793.","journal-title":"Cell Rep."},{"key":"2509_CR25","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/ng.3817","volume":"49","author":"J de la Rosa","year":"2017","unstructured":"de la Rosa J, Weber J, Friedrich MJ, Li Y, Rad L, Ponstingl H, et al. A single-copy Sleeping Beauty transposon mutagenesis screen identifies new PTEN-cooperating tumor suppressor genes. Nat Genet. 2017;49:730\u201341.","journal-title":"Nat Genet"},{"key":"2509_CR26","doi-asserted-by":"crossref","first-page":"7106","DOI":"10.1038\/s41388-019-0936-x","volume":"38","author":"L Pique","year":"2019","unstructured":"Pique L, Martinez de Paz A, Pineyro D, Martinez-Cardus A, Castro de Moura M, Llinas-Arias P, et al. Epigenetic inactivation of the splicing RNA-binding protein CELF2 in human breast cancer. Oncogene. 2019;38:7106\u201312.","journal-title":"Oncogene"},{"key":"2509_CR27","volume":"11","author":"Z Fan","year":"2021","unstructured":"Fan Z, Zhang Z, Piao C, Liu Z, Wang Z, Kong C. Genome-wide analyses of prognostic and therapeutic alternative splicing signatures in bladder urothelial carcinoma. Front Oncol. 2021;11:626858.","journal-title":"Front Oncol"},{"key":"2509_CR28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.7178\/ig.1.1.7","volume":"1","author":"S Ramalingam","year":"2012","unstructured":"Ramalingam S, Ramamoorthy P, Subramaniam D, Anant S. Reduced expression of RNA binding protein CELF2, a putative tumor suppressor gene in colon cancer. Immunogastroenterology. 2012;1:27\u201333.","journal-title":"Immunogastroenterology"},{"key":"2509_CR29","doi-asserted-by":"crossref","unstructured":"Sah B, Singh J, Shen Y, Goldfarb N, Samie FH, Geskin LJ et al. Loss of CELF2 promotes skin tumorigenesis and increases drug resistance. Int J Dermatol. 2025;64:101\u201310","DOI":"10.1111\/ijd.17295"},{"key":"2509_CR30","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/s41388-024-03006-3","volume":"43","author":"T Guo","year":"2024","unstructured":"Guo T, Wang Y, Sun X, Hou S, Lan Y, Yuan S, et al. Loss of RNA-binding protein CELF2 promotes acute leukemia development via FAT10-mTORC1. Oncogene. 2024;43:1476\u201387.","journal-title":"Oncogene"},{"key":"2509_CR31","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s42003-022-03250-x","volume":"5","author":"WW Teo","year":"2022","unstructured":"Teo WW, Cao X, Wu CS, Tan HK, Zhou Q, Gao C, et al. Non-coding RNA LEVER sequestration of PRC2 can mediate long range gene regulation. Commun Biol. 2022;5:343.","journal-title":"Commun Biol"},{"key":"2509_CR32","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-15059-5","volume":"11","author":"M Dietachmayr","year":"2020","unstructured":"Dietachmayr M, Rathakrishnan A, Karpiuk O, von Zweydorf F, Engleitner T, Fernandez-Saiz V, et al. Antagonistic activities of CDC14B and CDK1 on USP9X regulate WT1-dependent mitotic transcription and survival. Nat Commun. 2020;11:1268.","journal-title":"Nat Commun"},{"key":"2509_CR33","volume":"42","author":"BR Muys","year":"2023","unstructured":"Muys BR, Shrestha RL, Anastasakis DG, Pongor L, Li XL, Grammatikakis I, et al. Matrin3 regulates mitotic spindle dynamics by controlling alternative splicing of CDC14B. Cell Rep. 2023;42:112260.","journal-title":"Cell Rep."},{"key":"2509_CR34","doi-asserted-by":"crossref","first-page":"S195","DOI":"10.1007\/s00277-015-2326-y","volume":"94","author":"M Talpaz","year":"2015","unstructured":"Talpaz M, Mercer J, Hehlmann R. The interferon-alpha revival in CML. Ann Hematol. 2015;94:S195\u2013207.","journal-title":"Ann Hematol"},{"key":"2509_CR35","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1158\/1541-7786.MCR-10-0356","volume":"9","author":"M Albajar","year":"2011","unstructured":"Albajar M, Gomez-Casares MT, Llorca J, Mauleon I, Vaque JP, Acosta JC, et al. MYC in chronic myeloid leukemia: induction of aberrant DNA synthesis and association with poor response to imatinib. Mol Cancer Res. 2011;9:564\u201376.","journal-title":"Mol Cancer Res"},{"key":"2509_CR36","first-page":"2738","volume":"141","author":"V Krishnan","year":"2023","unstructured":"Krishnan V, Schmidt F, Nawaz Z, Venkatesh PN, Lee KL, Ren X, et al. A single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia. Blood. 2023;141:2738\u201355.","journal-title":"Blood"},{"key":"2509_CR37","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/0092-8674(92)90241-4","volume":"70","author":"CL Sawyers","year":"1992","unstructured":"Sawyers CL, Callahan W, Witte ON. Dominant negative MYC blocks transformation by ABL oncogenes. Cell. 1992;70:901\u201310.","journal-title":"Cell"},{"key":"2509_CR38","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/nchembio.1085","volume":"8","author":"GE Winter","year":"2012","unstructured":"Winter GE, Rix U, Carlson SM, Gleixner KV, Grebien F, Gridling M, et al. Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML. Nat Chem Biol. 2012;8:905\u201312.","journal-title":"Nat Chem Biol"},{"key":"2509_CR39","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/ajh.26650","volume":"97","author":"B Peter","year":"2022","unstructured":"Peter B, Eisenwort G, Sadovnik I, Bauer K, Willmann M, Rulicke T, et al. BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph(+) chronic myeloid leukemia. Am J Hematol. 2022;97:1215\u201325.","journal-title":"Am J Hematol"},{"key":"2509_CR40","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/B978-0-12-386469-7.00004-9","volume":"110","author":"LR Thomas","year":"2011","unstructured":"Thomas LR, Tansey WP. Proteolytic control of the oncoprotein transcription factor Myc. Adv Cancer Res. 2011;110:77\u2013106.","journal-title":"Adv Cancer Res"},{"key":"2509_CR41","doi-asserted-by":"crossref","first-page":"715","DOI":"10.18632\/oncotarget.990","volume":"4","author":"JM Gerber","year":"2013","unstructured":"Gerber JM, Gucwa JL, Esopi D, Gurel M, Haffner MC, Vala M, et al. Genome-wide comparison of the transcriptomes of highly enriched normal and chronic myeloid leukemia stem and progenitor cell populations. Oncotarget. 2013;4:715\u201328.","journal-title":"Oncotarget"},{"key":"2509_CR42","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3324\/haematol.2021.279317","volume":"107","author":"V Krishnan","year":"2022","unstructured":"Krishnan V, Kim DDH, Hughes TP, Branford S, Ong ST. Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers. Haematologica. 2022;107:358\u201370.","journal-title":"Haematologica"},{"key":"2509_CR43","doi-asserted-by":"crossref","unstructured":"Dvinge H, Bradley RK. Widespread intron retention diversifies most cancer transcriptomes. Genome Med. 2015;7:45","DOI":"10.1186\/s13073-015-0168-9"},{"key":"2509_CR44","volume":"24","author":"JS Shah","year":"2022","unstructured":"Shah JS, Milevskiy MJG, Petrova V, Au AYM, Wong JJL, Visvader JE, et al. Towards resolution of the intron retention paradox in breast cancer. Breast Cancer Res. 2022;24:100.","journal-title":"Breast Cancer Res"},{"key":"2509_CR45","volume":"11","author":"D Zhang","year":"2020","unstructured":"Zhang D, Hu Q, Liu X, Ji Y, Chao HP, Liu Y, et al. Intron retention is a hallmark and spliceosome represents a therapeutic vulnerability in aggressive prostate cancer. Nat Commun. 2020;11:2089.","journal-title":"Nat Commun"},{"key":"2509_CR46","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jare.2020.04.016","volume":"24","author":"SQ Li","year":"2020","unstructured":"Li SQ, Liu J, Zhang J, Wang XL, Chen D, Wang Y, et al. Transcriptome profiling reveals the high incidence of hnRNPA1 exon 8 inclusion in chronic myeloid leukemia. J Adv Res. 2020;24:301\u201310.","journal-title":"J Adv Res"},{"key":"2509_CR47","doi-asserted-by":"crossref","unstructured":"Schmitz U, Shah JS, Dhungel BP, Monteuuis G, Luu PL, Petrova V, et al. Widespread aberrant alternative splicing despite molecular remission in chronic myeloid leukaemia patients. Cancers (Basel). 2020;12:3738","DOI":"10.3390\/cancers12123738"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02509-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02509-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02509-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T16:09:38Z","timestamp":1741104578000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02509-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,7]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["2509"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02509-y","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,7]]},"assertion":[{"value":"13 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The research was approved by the institutional review board (National University Hospital, DSRB# 2015\/00804; DSRB#: 2007\/00173) and all human participants gave written informed consent. All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}